AVAna Karine Vieira

Ana Karine Vieira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Karine Vieira has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hematopoietic cell transplantation in inborn errors of immunity - Part II: others

    by Juliana Folloni Fernandes, Rafaella Muratori, Gisele Loth, Ana Karine Vieira, Paulo Klinger, Simone Franco, Carmem Bonfim

    Inborn errors of immunity (IEI) are a large, heterogeneous group of disorders resulting from deficiencies in immune system development and/or function, leading to increased susceptibility to infections, autoimmunity, autoinflammation, lymphoproliferation, and malignancy. Some diseases are classical hematopoietic cell transplantation (HCT) indications, such as Wiskott-Aldrich Syndrome, but more than 150 different IEI have been transplanted. Each disease and patient should be addressed individually as the clinical manifestations are variable, as well as the pre- and post-transplant care. This consensus strongly recommends that these patients are referred to experienced centers performing HCT for IEI.

  • Open Access

    Hematopoietic cell transplantation in inborn errors of immunity Part I: severe combined immunodeficiency

    by Rafaella Muratori, Juliana Folloni Fernandes, Gisele Loth, Ana Karine Vieira, Paulo Klinger, Simone Franco, Carmem Bonfim

    Severe Combined Immunodeficiencies (SCID) are rare diseases characterized by a blockage in T-lymphocyte development. Hematopoietic Cell Transplantation (HCT) is the primary curative therapy, with the highest survival rates correlated to early diagnosis and the absence of active infections at transplant. The gold standard is a matched related sibling donor (MSD), but alternative donors like haploidentical family donors are increasingly used. Conditioning regimens vary, with reduced intensity busulfan and fludarabine often indicated. Early diagnosis via newborn screening and referral to experienced HCT centers are crucial for improving outcomes. Long-term follow-up is essential, as the cumulative incidence of late effects, such as neurologic and neurodevelopmental issues, increases over time.

  • Open Access

    Hematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus

    by Luiz Guilherme Darrigo Junior, Ana Karine Vieira, Cilmara Kuwahara, Roseane Vasconcelos Gouveia, Paulo Klinger, Alexandre de Albuquerque Antunes, Julia Lopes Garcia

    Allogeneic hematopoietic cell transplantation (HCT) represents a critical therapeutic option for patients with transfusiondependent thalassemia (TDT), with thalassemia-free survival rates exceeding 90% in cases involving HLA-matched sibling donors. Due to the limited availability of matched donors, alternative sources such as HLA-matched unrelated donors, haploidentical donors, and umbilical cord blood have broadened HCT eligibility. Despite its potential for cure, HCT involves risks like graft-versus-host disease, graft rejection, and transplant-related mortality. Recent improvements in conditioning regimens have enhanced patient outcomes and quality of life. Factors affecting HCT success in TDT include recipient age, disease complications, effective chelation therapy, Pesaro score, and donor compatibility. This article aimed to update the Brazilian consensus established by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, incorporating the latest advances in treating and managing TDT patients undergoing transplantation.

  • Open Access

    Sickle cell disease

    by Luiz Guilherme Darrigo Junior, Roseane Vasconcelos Gouveia, Cilmara Kuwahara, Alexandre de Albuquerque Antunes, Adriana Martins de Sousa, Ana Karine Vieira, Ainá Henriques Melgaço, Juliana Folloni Fernandes, Adriana Seber

    Sickle cell disease (SCD) is known as the most common hemoglobin disorder, with severe forms of thalassemia syndromes following closely. Current standard treatments, including transfusions, hydroxyurea, and L-glutamine, still do not significantly improve life expectancy and quality of life for patients. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative option, showing overall survival and event-free survival rates over 90%, especially in patients under 16 years old. However, only 15% of SCD patients have access to an unaffected family donor. To increase donor availability, alternative sources such as matched unrelated donors, unrelated umbilical cord blood, and haploidentical donors have become viable options for patients without a matched related donor. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of patients with SCD undergoing HCT.

  • Open Access

    Hematopoietic cell transplantation in inherited bone marrow failure syndromes

    by Gisele Loth, Luiz Guilherme Darrigo Júnior, Adriana Martins de Sousa, Alexandre de Albuquerque Antunes, Ana Karine Vieira

    Inherited bone marrow failure syndromes (IBMFS) comprise a heterogeneous group of rare genetic disorders characterized by defective hematopoiesis, congenital anomalies, and a predisposition to clonal evolution and malignancies. Hematopoietic cell transplantation remains the only curative option for the hematologic manifestations of these disorders, although it does not correct congenital malformations or eliminate the long-term risk of non-hematopoietic cancers. This review summarized current evidence and transplantation strategies for major IBMFS, including Fanconi anemia, dyskeratosis congenita/telomere biology disorders, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, congenital neutropenia, congenital amegakaryocytic thrombocytopenia, and other inherited thrombocytopenias. We discussed disease-specific transplant indications, donor selection, conditioning regimens, graft source preferences, and outcomes across different patient populations. Advances in reduced-intensity conditioning and post-transplant cyclophosphamide have expanded donor availability, improving survival even with alternative donors. Nevertheless, long-term challenges persist, such as increased risks of solid tumors, endocrine dysfunction, and organ toxicity, emphasizing the need for multidisciplinary care and lifelong surveillance. Optimal outcomes depend on timely referral to specialized centers, meticulous donor screening, and individualized transplant strategies tailored to the unique biology of each disorder.

  • Open Access

    Long-term follow-up after pediatric hematopoietic stem cell transplantation

    by Polliany Roberta Dorini Pelegrina, Roseane Vasconcelos Gouveia, Antonio Vaz de Macedo, Ana Karine Vieira, Gabriela Gaspar Filgueiras Landi, Julia Lopes, Osvaldo Alves de Menezes Neto, Rafaela de Souza Ferreira, Adriana Aparecida Siviero Miachon, Rita de Cássia Barbosa da Silva Tavares, et al.

    This article, part of the Pediatric Group consensus of the Brazilian Society of Bone Marrow Transplantation, addresses lifelong follow-up in pediatric hematopoietic stem cell transplant survivors. With the growing number of long-term survivors, specialized monitoring is essential, especially for high-risk groups such as infants, recipients of total body irradiation, and those with inherited bone marrow failure syndromes. The consensus outlines surveillance strategies for detecting and managing late complications, including chronic graft-versus-host disease and secondary effects. Multidisciplinary recommendations aim to optimize early intervention and quality of life, establishing a standardized follow-up framework for pediatric transplant care in Brazil.


  • Open Access

    Peak nasal inspiratory flow in children and adolescents with sickle cell disease: a case-control study

    by Ana Karine Vieira, Cristina Gonçalves Alvim, Clara Polito Braga, Ricardo Reis Dinardi, Marcos Vinícius Domingues Borba, Ricardo Manoel Oliveira Rodrigues, Cássio da Cunha Ibiapina

    Sickle cell disease is the most frequent of the hereditary hemoglobinopathies and it presents multisystemic effects. A manifestation that is commonly found in sickle cell disease is upper airway obstruction, particularly adenotonsillar hypertrophy. This study aims to evaluate the peak nasal inspiratory flow measurements of children and adolescents with sickle cell disease. This is a case-control study on children aged between 8 and 15 years who were diagnosed with sickle cell disease. Peak nasal inspiratory flow measurements were obtained from patients. A total of 279 patients were enrolled in this study, with 93 in the case group and 186 in the control group. The case group had an 82.83% chance of having lower peak nasal inspiratory flow values than the control group. In the case group, 75% of the peak nasal inspiratory flow values were in the lower standards, whereas in the control group, only 25% were in the lower standards. This study showed a high prevalence of reduced peak nasal inspiratory flow values in children with sickle cell disease and could certainly be incorporated into the day-to-day clinical evaluation of patients as a screening instrument.